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Nicotinic Acetylcholine Receptor–Mediated Protection of the
Rat Heart Exposed to Ischemia Reperfusion
Spyros A Mavropoulos,1,4 Nayaab S Khan,1 Asaph CJ Levy,4 Bradley T Faliks,4 Cristina P Sison,2,4
Valentin A Pavlov,3,4 Youhua Zhang,5 and Kaie Ojamaa1,4,5
1

Center for Heart and Lung Research, 2 Biostatistics Unit, and 3 Center for Biomedical Sciences, The Feinstein Institute for Medical
Research, Northwell Health, Manhasset, New York, United States of America, 4Hofstra Northwell School of Medicine, Hofstra
University, Hempstead, New York, United States of America, and 5Department of Biomedical Sciences, New York Institute of
Technology College of Osteopathic Medicine, Old Westbury, New York, United States of America

Reperfusion injury following acute myocardial infarction is associated with significant morbidity. Activation of neuronal or
non-neuronal cholinergic pathways in the heart has been shown to reduce ischemic injury, and this effect has been attributed
primarily to muscarinic acetylcholine receptors. In contrast, the role of nicotinic receptors, specifically α-7 subtype (α7nAChR),
in the myocardium remains unknown, which offers an opportunity to potentially repurpose several agonists/modulators that are
currently under development for neurologic indications. Treatment of ex vivo and in vivo rat models of cardiac ischemia/reperfusion (I/R) with a selective α7nAChR agonist (GTS21) showed significant increases in left ventricular developing pressure and
rates of pressure development, without effects on heart rate. These positive functional effects were blocked by co-administration with methyllycaconitine (MLA), a selective antagonist of α7nAChRs. In vivo, delivery of GTS21 at the initiation of reperfusion
reduced infarct size by 42% (p < 0.01) and decreased tissue reactive oxygen species (ROS) by 62% (p < 0.01). Flow cytometry of
MitoTracker Red–stained mitochondria showed that mitochondrial membrane potential was normalized in mitochondria isolated
from GTS21-treated compared with untreated I/R hearts. Intracellular adenosine triphosphate (ATP) concentration in cultured
cardiomyocytes exposed to hypoxia/reoxygenation was reduced (p < 0.001), but significantly increased to normoxic levels with
GTS21 treatment, which was abrogated by MLA pretreatment. Activation of stress-activated kinases JNK and p38MAPK was
significantly reduced by GTS21 in I/R. We conclude that targeting myocardial α7nAChRs in I/R may provide therapeutic benefit
by improving cardiac contractile function through a mechanism that preserves mitochondrial membrane potential, maintains
intracellular ATP and reduces ROS generation, thus limiting infarct size.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2017.00091

INTRODUCTION
Cardiac contractility, pacemaker activity and conduction are controlled by
the autonomic nervous system, with catecholaminergic and cholinergic signals
originating from sympathetic and parasympathetic neural pathways. An imbalance in neurotransmission from these
two opposing neural pathways with
increased adrenergic and diminished

cholinergic activities has been observed
in heart failure and systemic hypertension, and with increasing age (7,9,33).
Experimental studies aimed at reducing
cholinergic neural activity using mice
deficient in muscarinic-acetylcholine
receptors (AChR) or vesicular acetylcholine transporters (VAChT) have
clearly shown that the parasympathetic
nervous system has a protective role in
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maintaining cardiac function (24,25).
Furthermore, vagus nerve stimulation
in animal studies and in patients with
heart failure has shown improvement
in cardiac function, suggesting that
cholinergic-pathway activation may
provide therapeutic benefit (5,18,45,53,).
Other studies using drugs to augment
the parasympathetic nervous system or
influence vagal tone, including acetylcholinesterase inhibitors such as donepezil or pyridostigmine, show evidence
of improved ventricular remodeling
and autonomic function in animal models of heart failure or after myocardial
infarction (13, 26,32, 37,42). Studies of
patients treated with these drugs for
Alzheimer’s dementia have reported reduced adverse cardiac events, including
myocardial infarction and death (31).

RESEARCH ARTICLE

Reports documenting the synthesis
and secretion of acetylcholine (ACh) by
the cardiomyocyte further implicate the
importance of non-neuronal cholinergic
signaling mechanisms in maintaining
the physiologic health of the myocardium (16,35,36). Evidence from various
transgenic mouse models suggests that
this autocrine/paracrine action of ACh
is cardioprotective under stressful conditions, such as cardiac hypertrophy and
failure, as well as ischemic injury (17,39).
However, the molecular mechanisms by
which ACh elicits these effects remain
unclear. ACh initiates its cellular signal
by activating G-protein–coupled muscarinic receptors (M2, M3) or by binding to
nicotinic receptors (nAChR) that are ligand-gated ion channels, and both receptor types are present in the heart (2,10).
Although the well-known effects of neuron-derived ACh on heart-rate response
have been attributed to muscarinic
receptor activation on atrial cells, the effects of ACh acting on nicotinic receptors
remain largely unknown (reviewed in
[40]). Dvorakova et al. (10) showed by
immunohistochemistry of rat hearts that
nicotinic α7 subunits localize to cardiac
neurons, fibroblasts and cardiomyocytes,
and that α2/α4 subunits concentrate
at myocyte intercalated discs. More recently, Gergalova et al. (11,12) identified
α7nAChRs in liver mitochondria outer
membranes that function to regulate
mitochondrial permeability transition
pore (mPTP) formation through kinasemediated signaling pathways, thus
preventing cytochrome c release and
attenuating apoptosis. The presence of
α7nAChRs in cardiac mitochondria has
not been reported. However, this finding
would be of particular significance in
cardiac ischemia/reperfusion (I/R), since
reactive oxygen species (ROS) generation and influx of calcium, which occur
during reperfusion, trigger formation of
the mPTP, leading to depolarization of
the mitochondrial membrane, organelle
swelling and rupture, release of cytochrome c and cell death (14).
We focused the present study on the
potential therapeutic utility of activating

nicotinic receptors, specifically α7nACh,
to reduce reperfusion injury after acute
myocardial infarction. The rationale for
the study was that the process of reperfusion after a period of ischemia can further
induce cardiomyocyte death, for which
no effective treatment currently exists,
and intervention at this time period may
be most effective in decreasing myocyte
injury and subsequently enhancing recovery of cardiac function (reviewed in [14]).
MATERIALS AND METHODS
Reagents
GTS-21 (3-(2,4-dimethoxy-benzylidene)
anabaseine dihydrochloride; DMXB-A)
and methyllycaconitine citrate salt hydrate (MLA) were purchased from Sigma
Aldrich (St. Louis, MO) and galantamine
hydrobromide from Calbiochem (San
Diego, CA). Cell culture reagents and
media were purchased from Gibco (ThermoFisher Scientific, Waltham, MA). All
other reagents and chemicals were of the
highest quality and purity, purchased
from commercial sources.
Animal Models
All animals were treated in accordance
with the National Institutes of Health
Guidelines for the Use and Care of Laboratory Animals (HHS Pub. No. 85-23),
and study protocols were approved by
the Institutional Animal Care and Use
Committee of The Feinstein Institute for
Medical Research.
Isolated perfused hearts. Animals
were randomized to treatment groups
on the day of study. Hearts from male
Sprague-Dawley rats (310g ± 20g)
(Taconic Biosciences, Inc., Hudson, NY)
were isolated and perfused in retrograde
mode at a constant pressure of 90 mmHg
at 37°C as previously described (19).
Briefly, rats were heparinized (100 Units)
prior to anesthesia (sodium pentobarbital, 60 mg/kg intraperitoneally), hearts
rapidly removed and perfused with modified Krebs-Henseleit buffer (KHB; Sigma
Aldrich), which was freshly prepared
with the addition of calcium chloride
and sodium bicarbonate according to the

manufacturer’s instructions. Contractile
function was assessed using a pressure
transducer coupled to a water-filled latex
balloon inserted into the left ventricle
through the mitral valve and inflated to
an initial end diastolic pressure (EDP) of
~5 mmHg. Hearts were equilibrated for
10 min with KHB and then perfused with
KHB containing vehicle or drugs for 10
min prior to initiation of normothermic
global ischemia, by stopping perfusion
for 30 min, followed by 40 min reperfusion with KHB. Drugs were delivered
prior to the ischemic period, because the
perfusion flow rate is very low following
ischemia, preventing the rapid delivery
of drugs. Left ventricular (LV) pressures
were recorded continuously throughout
the perfusion period, and functional
values for each heart were calculated as
percent of values recorded at the end of
the 10 min equilibration period. Function measurements recorded were: left
ventricular developed pressure (LVDP),
rate of pressure development and rate
of relaxation (± dP/dt) and heart rate
(HR). Work product (WP) was calculated
by multiplying LVDP by HR. Drug concentrations delivered were: GTS21 (1.6 ×
10-8 M), methyllycaconitine (MLA) (2.33
× 10-7 M), galantamine (5 × 10-8 M) and
combined GTS21 + MLA (same dosing).
Hearts were excluded from the study if,
during the equilibration period, perfusion rate was <10 mL/min, HR was <100
bpm, LVDP was <100 mmHg or sustained arrhythmic events were recorded.
Perfusion control hearts were not subject
to ischemia but were perfused for the
same length of time as I/R hearts.
In vivo studies. Female Sprague-Dawley
rats (230–300 g) (Taconic Biosciences, Inc.)
were randomized to sham surgery or I/R,
treated with either saline or GTS-21.
The animals were fully anesthetized with
sodium pentobarbital (80 mg/kg), the
chest and neck were shaved and the skin
cleaned with betadine and alcohol. Animals were orally intubated and mechanically ventilated (Harvard Apparatus,
Holliston, MA) with room air at a tidal
volume of 1 mL/100 g body weight and
a respiratory rate of 60 breaths/min.
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Core body temperature was maintained at
~36°C using a heating pad and was monitored continuously. A left thoracotomy
exposed the heart, the pericardial sac was
opened and the left anterior descending
(LAD) coronary artery at the level of the
left atrium was ligated with 6-0 braided
silk suture around a 4 mm length of PE-50
tubing to prevent vessel injury. The LAD
was occluded for 30 min, and then reperfusion was initiated by removing the PE
tubing. At the start of reperfusion, GTS-21
(0.125 mg/kg in 0.2 mL saline) or saline
was injected as a bolus via a cannula (PE50 tubing) placed in the right femoral vein
or the left common carotid artery. After 60
min of reperfusion, the LAD was occluded
again by tightening the suture, and 2 mL
of Evans blue dye solution (7%) was injected into the circulation via the left
common carotid artery to delineate the
perfused heart tissue from the nonperfused area at risk (AAR). After approximately 2 min of perfusion with dye, the
heart was excised and sectioned along
the short axis into five or six 2 mm slices
that were incubated in 2,3,5-triphenyl-
tetrazolium chloride solution (TTC, 1% in
phosphate-buffered saline [PBS]; Sigma
Aldrich) for 30 min at 37°C to define viable
and nonviable tissue within the AAR. Infarct size and AAR were measured by one
individual as previously described (23).
In Vivo Hemodynamic Analysis
Left ventricular hemodynamic measurements were recorded in animals that
were not used to measure infarct size.
At the end of the I/R period described
above, a 1.4-Fr Millar pressure catheter
(SPR-671; Millar Instruments, Houston,
TX) was inserted into the right carotid
artery and advanced into the left ventricle. LV pressures were recorded over
a 5 min period and data were collected
using PowerLab 8/30 acquisition system
(AD Instruments, Colorado Springs,
CO) and analyzed with LabChart Pro
software. Control LV pressures were
obtained from a separate group of sham
operated animals that underwent identical experimental surgical procedures
without occlusion of the LAD.

Tissue Homogenization, Fractionation
and Immunoblot Analysis
Hearts were excised, rapidly frozen
in liquid nitrogen and stored at –80°C.
For immunoblot analysis, the LV free
wall from the in vivo studies was used,
whereas the entire LV from perfused
hearts was used. Frozen tissue was
homogenized in 10 volumes of ice-cold
buffer (50 mM Tris HCl, pH 7.5, 150
mM NaCl, 2 mM EDTA, phosphatase/
protease inhibitor cocktail; Cell Signaling Technologies, Danvers, MA) using
glass mortar and motor-driven Teflon
pestle. The homogenate was centrifuged at 1,000g for 10 min at 4°C, and
the resulting supernatant was collected
and centrifuged at 10,000g for 30 min
at 4°C to obtain the cytosolic fraction.
Protein concentrations were measured
using Micro BCA Assay (Pierce, Rockford, IL). Samples of 50 μg proteins
were resolved on 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis and transferred onto nitrocellulose
membranes, which were treated as
necessary with Miser Antibody Extender Solution NC (Thermo Scientific,
Rockford, IL). Equal amounts of each
sample were run on parallel gels to
quantify total and phosphorylation of
the stress-activated proteins. Immunoblots were probed overnight at 4°C
using the following primary antibodies
(dilutions): phospho-JNK (1:10,000)
(cat. no. 9251), JNK (1:10,000) (cat. no.
9252S), phospho-p38 MAPK (1:10,000)
(cat. no. 9211) and p38 MAPK 1:10,000
(cat. no. 9212) from Cell Signaling
Technologies; α7 nicotinic acetylcholine receptor (1:500) (cat. no. ANC-007;
Alomone Labs, Jerusalem, Israel); and
GAPDH (1:100,000) (Sigma Aldrich).
Signals from horseradish peroxidase–
conjugated secondary antibodies were
developed using chemiluminescence reagent (Thermo Scientific) and detected
on either x-ray film or ChemiDoc MP
(BioRad, Hercules, CA). Images on film
were quantified using ImageJ (National
Institutes of Health, Bethesda, MD), and
ChemiDoc images were quantified using
BioRad Image Lab.
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Measurement of Tissue ROS
At the end of the I/R protocol for the
in vivo studies, hearts were removed,
rinsed in ice-cold saline and embedded in tissue-freezing medium for
cryosectioning. Eight micrometer thick
cross-sectional slices were cut serially,
starting from the basal area of the heart,
and mounted on histological slides,
then incubated in PBS for 30 min. The
slides were stained with dihydroethidium (DHE) for 30 min as previously
published (22). Images of the stained
slides were obtained immediately using
a Leica DMI 4000B microscope (Leica
Microsystems Inc., Buffalo Grove, IL) at
200 × magnification with an excitation
wavelength of 551 nm. Light intensity
measurements were recorded from three
independent areas of each tissue slice,
and data from three slices per heart were
analyzed. Fluorescence intensity was
quantified using Image Studio Lite v.3.1
(Licor, Lincoln, NE) and presented as
arbitrary units.
Isolation of Mitochondria
Mitochondria were isolated from perfused LV tissue (60 mg) immediately at
the end of the protocol, using a commercially available mitochondrial isolation kit
(Sigma Aldrich) according to the manufacturer’s instructions. This model of normothermic global ischemia assumes that
the entire LV is involved. In brief, tissue
was minced on a glass plate cooled on ice,
washed in ice-cold buffer (10 mM HEPES,
pH 7.5, 200 mM mannitol, 70 mM sucrose,
1 mM EGTA), and then digested with
trypsin for 20 min at 37°C. Digestion was
stopped with bovine serum albumin, and
the tissue was homogenized using a Teflon-on-glass homogenizer. The homogenate was centrifuged at 600g for 5 min at
4°C, and the supernatant collected and
centrifuged at 11,000g for 10 min at 4°C
to obtain the pellet containing the mitochondria. The pellet was resuspended in
storage buffer (10 mM HEPES, pH 7.5,
0.25 M sucrose, 1 mM ATP, 0.08 mM
ADP, 5 mM sodium succinate, 2 mM
K2HPO4, 1 mM DTT), and aliquots for
single use were stored at –80°C.
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Measurement of Mitochondrial
Membrane Potential
Isolated heart mitochondria (25 μg
protein in 5 μL) from the various treatment groups were added to 950 μL
assay buffer (20 mM MOPS pH 7.5, 110
mM KCl, 10 mM ATP, 10 mM MgCl2,
10 mM sodium succinate, 1 mM EGTA)
plus 45 μL of storage buffer provided
in the mitochondrial isolation kit described above. MitoTracker Red FM
(Molecular Probes, Eugene, OR) was
added to the mitochondria to achieve
a final concentration of 2 × 10-7 M and
incubated on ice for 30 min. Mitochondrial fluorescence was analyzed
with an LSR Fortessa flow cytometer
(Becton Dickinson, Franklin Lakes, NJ).
Excitation was achieved using the 640
nm laser. Gating parameters on the
flow cytometer were established using
a control mitochondrial sample and
adjusting the voltages for the forward
scatter, side scatter and MitoTracker
Red laser so that the histograms for
each laser had population peaks >102
but <103. All samples were run one
after the other on the same day with the
same settings. Samples of mitochondria isolated from perfusion control
hearts were used to establish the gating
parameters, and 10,000 events were collected for each sample. GTS21-treated
I/R and vehicle-treated I/R mitochondria samples were analyzed using the
established control gating parameters,
and the data are expressed as the
percent of total mitochondria in each
treatment sample that localized within
the established control mitochondria
gating parameters. The FACS data were
analyzed using FlowJo software v10
(Ashland, OR). Mitochondria isolated
from untreated hearts were incubated
with either antimycin A (2 × 10-4 M )
or oligomycin (10-6 M) (ThermoFisher
Scientific, Ward Hill, MA) for 30 min
prior to MitoTracker Red staining and
analyzed by fluorescence-activated cell
sorting (FACS) to identify the gating
parameters of mitochondria that were
maximally depolarized or hyperpolarized, respectively.

Neonatal Rat Ventricular Myocytes
(NRVMs)
Hearts of 2-d-old rat pups
(Sprague-Dawley) were digested with
collagenase to isolate ventricular myocytes
as previously published (21). Experiments were repeated on a second independent isolation of primary ventricular
myocytes to verify the results obtained.
In brief, NRVMs were plated on collagen-coated 35 mm dishes and cultured
for 48 h in Dulbecco’s Modified Eagle’s
Medium (DMEM)/F12 medium containing 10% fetal bovine serum, L-glutamine
and cytosine β-D-arabino-furanoside
(Ara C) (10-5 M) that was refreshed daily.
Cells were exposed to normoxic or hypoxic conditions for 8 h, followed by
treatment with vehicle or GTS21 (10-9 M)
during reoxygenation. The 8-h-hypoxic
time period initiated apoptotic signaling
events (data not shown). Cells were
harvested at various time points after
initiation of reoxygenation. In normoxic
conditions, cells were maintained in
low-glucose DMEM containing insulin
(120 IU/L), transferrin (5 mg/L) and
selenium (5 μg/L) (ITS), while cells in
hypoxic conditions were maintained in
DMEM without insulin, glucose and
pyruvate. During reoxygenation, media
were replaced with low-glucose DMEM
containing TS without insulin. Hypoxic
conditions were established by placing
the cell culture plates in a small airtight
plexiglass chamber (BioSpherix, Parish,
NY) infused with a mixture of 95% nitrogen/5% CO2 gas to maintain <0.2%
oxygen content under humidified 37°C
conditions. For normoxia and reoxygenation conditions, cells were placed in a
standard humidified cell culture incubator
maintained at 37°C and room air/5% CO2.
For immunocytochemistry, the cardiomyocytes were plated onto collagen-coated glass coverslips placed in
6-well plates and cultured for 4 d as
described above. After cells were washed
with Hank’s Balanced Salt Solution, they
were fixed with freshly prepared 2%
paraformaldehyde in PBS for 15 min, followed by several washes in PBS with
1% glycine. Cells were permeabilized

with 0.1% TritonX-100 in PBS, then
washed and blocked with 10% goat
serum for 1 h at room temperature. Cells
were incubated overnight at 4°C with the
following primary antibodies diluted
in 1% goat serum/PBS solution: α7 nicotinic acetylcholine receptor diluted 1:50
(cat. no. ANC-007; Alomone Labs), isotype-control rabbit IgG diluted 1:25
(cat. no. sc-2027; Santa Cruz Biotechnology,
Dallas, TX). After several washes, cells
were incubated with secondary antibody
Alexa Fluor 488 goat anti-rabbit IgG diluted 1:100 (cat. no. A-11008; Invitrogen,
Waltham, MA) and for F-actin staining,
TRITC-conjugated phalloidin diluted
1:500 (Sigma Aldrich,) for 1 h at room
temperature and protected from light.
The coverslips were mounted onto slides
using Fluoroshield Mounting Medium
containing 4’,6-diamidino-s-phenylindole
(Abcam, Cambridge, MA) for nuclear
staining. Images were captured at 630 ×
magnification using the Zeiss Axiocam
ER C5S (Carl Zeiss AG, Oberkochen,
Germany). Wavelength settings and
exposure times were maintained when
comparing fluorescence emitted from
cells incubated with control IgG isotype
and with anti-α7nAChR antibody.
Western Blot Analysis of NRVM
Cells were homogenized in lysis buffer
containing final concentrations of 50 mM
Tris HCl, pH 7.4, 150 mM NaCl, 1
mM EDTA, 1% NP-40 and protease/
phosphatase inhibitor (Cell Signaling
Technologies, cat. no. 5872), followed by
centrifugation at 13,000 rpm for 10 min
at 4°C. Protein concentrations of the supernatants were measured using Micro
BCA Assay, and samples of 30 μg
protein were resolved on 10% sodium
dodecyl sulfate polyacrylamide gel
electrophoresis and transferred onto
nitrocellulose membranes as described
above. Phospho-proteins and their total
nonphosphorylated isoforms were analyzed consecutively by stripping the
anti-phosphoprotein antibody, then incubating with the anti-nonphosphoprotein antibody on the same blot. Primary
antibodies used for immunoblot analysis
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were from Cell Signaling Technologies:
phospho-p44/42 MAPK (cat. no. 9106,
1:3000), p44/42 MAPK (cat. no. 9102,
1:10,000), pJNK, JNK, p-p38MAPK and
p38MAPK. Secondary antibodies used
were either goat anti-rabbit (BioRad,
cat. no. 170-6515) or goat anti-mouse
(BioRad, cat. no. 170-6516) IgG conjugated with horseradish peroxidase.
Proteins were detected using chemiluminescence reagent Super Signal West
Femto (ThermoFisher Scientific, cat. no.
34096), visualized using Chemidoc-MP
(BioRad), and densitometric analysis was
performed using Image Labs software
(BioRad).
Adult Human Cardiomyocytes (AC16)
AC16 cells (adult human cardiac
muscle cell line; ATCC, Bethesda, MD)
were cultured as previously published
(28). These immortalized cells, as originally developed and described by
Davidson et al. (4), exhibit many biological and morphological characteristics of
cardiac muscle cells. This cell line is not
listed by the International Cell Line Authentication Committee as misidentified.
FACS Analysis of `7nAChR Expression
on AC16 Cells
Adherent cultured AC16 cells were
dissociated with an enzyme-free buffer
(Gibco/ThermoFisher, Grand Island,
NY) and collected by centrifugation.
Cells were resuspended in MACS buffer
(Miltenyi Biotec, Gladbach, Germany)
to a final density of 300,000 cells/tube,
and then incubated for 30 min on ice
with anti-α7nAChR antibody (0.5 μg/
tube) (cat. no. ANC-007; Alomone) or
antibody preincubated for 1 h with its
blocking immunogen or isotype control IgG. Cells were then washed twice
with MACS buffer and incubated with
PE-conjugated anti-rabbit antibody
(2μg/mL) (cat. no. 4052-09; Southern
Biotech, Birmingham, AL) for 30 min on
ice, then washed twice and resuspended
in MACS buffer. Identification of cellassociated α7nAChR was determined
by flow cytometry (LSR Fortessa). Excitation was achieved using a 488 nm laser

with a 575/26 filter. Gating parameters
were FCS at 110 V with a threshold of
5000, SCC at 308 V and PE at 214 V;
30,000 events were collected for each
sample. The FACS data were analyzed
using FlowJo software v10.
Measurement of Intracellular ATP
Concentration
AC16 cells were grown on collagen-coated 6-well dishes at a density of
200,000 cells/well in DMEM containing
10% fetal bovine serum. Cells were exposed to normoxic or hypoxic conditions
(described above) for 6 h, followed by
1 h reoxygenation in low-glucose serum-free DMEM with or without GTS21
(10-9 or 10-8 M) or pretreated with MLA
(10-7 M). The 6-h-hypoxic period was
chosen based on our prior studies showing induction of apoptotic events (data
not shown). Cells were harvested in
200 μL 50 mM Tris-1mM EDTA pH 7.4
buffer containing 0.2% NP40, flashfrozen and stored at –80°C. Samples
were lysed by passing through a 26 G
needle, an aliquot used for protein determination (Micro BCA Assay, Pierce) and
25 μL boiled in 975 μL Tris-EDTA for
2 min. The boiled sample was clarified at
1,000g at 4°C and the final supernatant
diluted 1:4000 with water. A luciferase/
luciferin reaction mixture was prepared
by adding luciferase (1.2 × 109 U/mL;
Sigma Aldrich) and luciferin (0.2 mM;
Sigma Aldrich) to buffer containing
50 mM Tris-acetate, pH 7.9, 10 mM
magnesium acetate, 1 mM EGTA and
100 mM DTT. Ten μL of diluted sample
was added to 100 μL of the luciferase/
luciferin reaction mixture and read
immediately in a luminometer (Turner
Model TD-20, Madison, WI). ATP content was calculated using a standard
curve, and values were normalized to
protein concentration in the sample.
Statistical Analysis
Data are presented as the mean ±
standard error (or standard deviation,
as indicated). Sample numbers per
group are indicated in the Results section and figure legends. Statistical
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analysis was performed using twotailed Student t test or one-way analysis
of variance (ANOVA), followed by
post hoc analysis using Newman-Keuls
test. All data passed tests for normality
distribution and equal variance (SigmaStat 3.1; Systat Software, Richmond,
CA). For statistical analysis of the five
outcome variables measured in the perfused hearts (LVDP, + dP/dt, -dP/dt, HR,
WP) that were recorded continuously
during the reperfusion period, a mixed
model applied to repeated-measures
ANOVA (RMANOVA) was performed
on values at 0, 5, 10, 15, 20 and 30 min
to determine if measurements varied
significantly over time and between the
four treatment groups (I/R + vehicle,
I/R + GTS21, I/R + GTS + MLA, I/R +
MLA). Adjusted pairwise comparisons
were made between treatment groups
at each time point, and differences in
values were considered statistically
significant at p < 0.01. In the galantamine studies, RMANOVA was used
for comparisons of vehicle- and galantamine-treated perfused I/R hearts
with respect to the patterns of change
in each of the five outcome variables,
except that log-transformed values of
the raw data were used, since the standard model assumptions were not met
for all outcome variables. Results were
then back-transformed and are reported
using the geometric means and corresponding standard errors. Statistical
analysis was performed using SAS v9.3
(Cary, NC).
RESULTS
Cholinergic Pathway Activation
Improves LV Function during
Reperfusion
Isolated perfused heart experiments.
The experimental protocol for perfusion
of the isolated rat heart is depicted in
Figure 1A. As evident in Figure 1B, at
90 min total perfusion time, the LVDP
of control hearts decreased below 80%
of their pre-ischemia values. Therefore,
assuming that contractile function of
all isolated perfused hearts deteriorates
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Figure 1. α7nAChR activation with GTS21 treatment improved contractile function of I/R perfused rat hearts. (A) Experimental protocol of
the rat heart perfusion studies. Equil, equilibration period. (B–F) LV pressures were recorded during the 40 min reperfusion period and five
outcome variables (LVDP, + dP/dt, -dP/dt, heart rate [HR], work product [WP]) were measured at 0, 5, 10, 15, 20, 30 and 40 min and are
expressed as percent of the value measured at the end of the equilibration period (% pre-ischemia). Data points represent treatment
group mean ± SE. Perfusion control (•, n = 5); I/R + vehicle (▪, n = 4); I/R + GTS21 (▴, n = 6); I/R GTS21 + MLA (○, n = 3). I/R + MLA
(x , n = 3). RMANOVA performed on the five outcome variables measured at six time points (0–30 min) showed significant group × time
interactions in (B), (C) and (F), and pairwise comparisons between the four treatment groups showed significance at individual time
points as indicated: *p < 0.01 versus I/R, **p < 0.001 versus I/R, ***p ≤ 0.0001 versus I/R, τp < 0.01 versus GTS + MLA, γp < 0.01 versus MLA.

M OL M E D 2 3 : 1 2 0 - 1 3 3 , 2 0 1 7 | M a v r o p o u l o s E T AL . | 1 2 5

CHOLINERGIC-MEDIATED CARDIOPROTECTION

with perfusion time, the statistical analysis that was used for these studies utilized LV pressures recorded from 0 to
30 min reperfusion.
In preliminary studies, the optimum
treatment dose of GTS21 was determined empirically by measuring LV
function through a concentration range
from 10-7 to 10-9 M and was the dose
that produced the highest recovery of
LVDP during reperfusion (data not
shown). Thus, delivery of GTS21 at the
optimum dose (1.6 × 10-8 M) to perfused
rat hearts prior to ischemia significantly
improved LV function during the
reperfusion period compared with vehicle-treated ischemic hearts, and this effect of GTS21 was blocked by co-administration of MLA, a selective α7nAChR
antagonist. This effect reached statistical significance at 20 and 30 min of
reperfusion (Figure 1B). MLA treatment
alone of the I/R hearts had no effect
on any outcome variables, thus supporting the specificity of its effect. In
addition to LVDP, the maximum rate
of LV pressure development (+ dP/dt)
showed significant improvement with
GTS21 treatment versus vehicle-treated
I/R (Figure 1C), whereas the improvement in –dP/dt did not reach statistical
significance (Figure 1D). These positive
effects of GTS21 treatment on LV function occurred without any significant
changes in heart rate (Figure 1E). The
increase in WP, a function of heart rate
× LVDP, with GTS treatment reached
significance at 15 and 20 min of reperfusion (Figure 1F). GTS21 treatment
of control perfused hearts that were
not exposed to ischemia had no significant effect on LV pressure measurements recorded over 30 min (data not
shown). End diastolic pressure (EDP)
increased during the final 10–15 min
of the ischemic period to 37 ± 3 mmHg
in I/R hearts, which decreased to 21 ±
6 mmHg with GTS. The maximum increases in EDP for the MLA and MLA
+ GTS treated groups were 44 ± 15 and
36 ± 11 mmHg, respectively. However,
EDP data were not statistically different
among the groups. Irregular rhythmic

events occurred early in the reperfusion
period for all hearts regardless of treatment. The total time spent in arrhythmia recorded as seconds during 30 min
of reperfusion were 325 ± 208, 353 ±
144, 469 ± 239 and 662 ± 296 for the I/R
+ vehicle, I/R + GTS, I/R + MLA and
I/R + GTS + MLA groups, respectively.
Differences among groups were not statistically significant.
Galantamine (5 × 10-8 M), a cholinesterase inhibitor and positive allosteric
modulator of α7nAChR, was similarly
delivered prior to ischemia and resulted
in significantly higher LV functional
measurements without HR changes compared with vehicle-treated I/R hearts
(Table 1).
In vivo cardiac I/R. Studies were undertaken to evaluate the effects of GTS21
treatment on rat myocardial I/R injury
in vivo. GTS21 was delivered intravenously at the initiation of reperfusion in
the dose range of 0.06–1.0 mg/kg, and it
was determined that 0.125 mg/kg

produced the maximum recovery of LV
function after 60 min of reperfusion.
This dose of GTS21 was used in all
experiments. All measurements of LV
function, including LVDP, + dP/dt and
-dP/dt, recorded at 60 min of reperfusion showed significant improvement
with GTS21 treatment compared with
vehicle-treated animals (Table 2). Similar to the perfused heart experiments,
heart rate was unaffected by GTS21.
Work product was significantly higher
(p < 0.001) in GTS-treated than vehicle-treated I/R animals, but remained
lower (p < 0.05) than in
sham-operated animals.
The improvement in LV function observed in response to GTS21 treatment
of I/R animals was further supported
by the significant (p < 0.01) reduction of
myocardial infarct size relative to AAR
(INF/AAR, %) compared with vehicle-treated I/R hearts (32 ± 4% versus 55
± 3%, respectively) (Figure 2A). This reduction in myocardial tissue injury was

Table 1. Left ventricular pressure measurements of isolated rat hearts recorded after
ischemia during the reperfusion period.
†Function, %pre-ischemia
LVDP
+dP/dt
–dP/dt
HR
WP

I/R + vehicle

I/R + Galantamine

36.8 ± 12.4
20.2 ± 8.7
25.7 ± 14.2
48.0 ± 21.7
17.8 ± 11.9

72.6 ± 17.6*
46.9 ± 14.7*
45.6 ± 11.3*
53.4 ± 7.8
38.5 ± 10.5*

†

Functions are LV pressures calculated as percent pre-ischemia values. Values are
mean ± SD recorded at 30 min of reperfusion. LVDP, LV developed pressure; ± dP/dt, min
or max developed pressure over time; HR, heart rate; WP, work product. RMANOVA was
performed on data recorded between 0 and 30 min of reperfusion. Adjusted pairwise
comparisons between the treatment groups show significant differences, with *p < 0.05
versus vehicle; n = 4/group.
Table 2. Myocardial contractile function measured in vivo in a rat model of I/R.
Function (post-I/R)
LVDP (mmHg)
+dP/dt (mmHg⋅sec-1)
-dP/dt (mmHg⋅sec-1)
HR (bpm)
WP (mmHg⋅bpm)

Sham surgery (n=6)
119 ± 18
5542 ± 1106
-6860 ± 1580
396 ± 27
47175 ± 9000

I/R + veh (n=10)

I/R + GTS (n=10)

66 ± 15***
3640 ± 1441**
-3061 ± 1487***
380 ± 40
25544 ± 7953***

97 ± 14*†
5648 ± 576†
-5636 ± 1423†
395 ± 40
38393 ± 6630*†

One-way ANOVA with Student-Neuman-Keuls post hoc pairwise multiple-comparison
test performed. *p < 0.05, **p < 0.01, ***p < 0.001 versus sham; †p < 0.001 versus I/R + veh;
values are mean ± SD; (n) = number of animals/group.
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Figure 2. GTS21 treatment at reperfusion reduced infarct size and ROS and improved
contractile function in vivo in a rat model of I/R. (A) Myocardial area at risk (AAR) as
percent of LV area in rats receiving vehicle (veh, n = 6 ) or GTS21 (GTS, n = 6 ) (no
statistical difference between groups); data are mean ± SE. Infarct size (INF) expressed
as percent AAR. Statistical significance was determined by Student t test. *p < 0.01
versus I/R + veh. (B) Representative images of DHE staining of 8 μm frozen sections of
LV free wall in sham, I/R + veh and I/R + GTS21 groups; 200 × magnification; excitation
wavelength, 551 nm. (C) Quantitation of DHE fluorescence (AU, arbitrary units) in microscopic images using Image Studio Lite v3.1. Staining intensity was measured in three
independent areas in three sequential sections per heart. n = 5 hearts/group; bar graph
represents group mean ± SE. Statistical significance determined by one-way ANOVA.
*p < 0.01 versus sham and I/R + GTS.

reflected in a significant (p < 0.01) reduction in ROS generation as measured by
fluorescence microscopy of dihydroethidium (DHE) staining of cross-sectional
LV slices (Figure 2B). Quantitation of
the intensity of DHE staining showed
that the increase of ROS in I/R hearts
was significantly reduced in the GTS21treated animals to a level that was not
different from sham-operated control
animals (Figure 2C).

Mitochondrial Membrane Potential
Normalized by GTS21 Treatment
Mitochondria play an integral role
in ROS generation and are key determinants of cell survival following I/R
injury. To determine whether maintaining mitochondrial integrity was integral
to the cytoprotective effects of GTS21
in myocardial I/R injury, mitochondria
were isolated from perfused hearts
to measure mitochondrial membrane

potential (ΔΨM) using a mitochondrionselective fluorophore (MitoTracker Red).
FACS analysis was used to determine
ΔΨM by measuring the fluorophore
signal intensity in each mitochondrion
(Figure 3A). To identify mitochondria
membrane potentials as either hypopolarized or hyperpolarized, mitochondria
samples were treated with antimycin A
or oligomycin, respectively, and this is
shown in the histogram as peak-a and
peak-e (Figure 3B). Staining intensity of
mitochondria isolated from I/R-vehicle
treated hearts shows that these organelles were hyperpolarized (peak-d) compared with mitochondria from perfusion
control (PC) (i.e., nonischemic) hearts
(peak-b). GTS21 treatment of I/R hearts
normalized mitochondrial membrane
potentials (peak-c) to the ΔΨM measured
in mitochondria from perfusion control
hearts (peak-b). These results were quantified as the percent of total mitochondria
in each treatment group that fell within
the gating parameters encompassing mitochondria from perfusion control
hearts, as indicated by the quadrangle
in Figure 3A. As shown in the bar graph
(Figure 3C), GTS21 treatment during I/R
significantly increased (p < 0.01) the percent of mitochondria that localized within
the established gating parameters, indicating that these mitochondria had the same
ΔΨM as mitochondria from PC hearts.
GTS21 Attenuates I/R-Activated
Intracellular Stress Pathways In Vivo
and Ex Vivo
Expression of α7nAChR protein was
not different in ex vivo perfused hearts
or in vivo hearts subjected to I/R with or
without GTS21 treatment (Figures 4A, B).
To identify potential molecular mechanisms by which α7nAChR activation
resulted in attenuated infarct size, mitochondrial preservation and improved
contractile function, we measured intracellular signaling pathways known
to regulate cell death and survival.
Immunoblot analysis of stress-activated
JNK and p38MAPK proteins in perfused
hearts subjected to I/R showed significant increases in phosphorylation, thus
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Figure 3. Membrane potential of mitochondria isolated from perfused rat hearts. (A)
MitoTracker red dye used to measure mitochondria membrane potential (ΔΨm) by flow
cytometry. Scatter plot showing individual mitochondria sorted by side scatter (SSC) and
fluorescence intensity of MitoTracker dye. Red dots are mitochondria from I/R hearts, blue
dots are from perfusion control (PC) nonischemic hearts and green dots are from GTS21treated I/R hearts. The established gating parameter is indicated by the black lines encircling the PC mitochondria. (B) Histograms represent numbers of mitochondria counted
and the intensity of MitoTracker red staining of those mitochondria isolated from each
treatment group: a, antimycin A–treated mitochondria (hypopolarization); b, perfusion
control (PC); c, I/R + GTS21; d, I/R + veh; e, oligomycin A–treated mitochondria (hyperpolarization). (C) Bar graph quantifying the percentage of total mitochondria in each treatment group that fell within the gating parameters established for the perfusion control
mitochondria. Values are mean ± SE; PC, n = 3; I/R + GTS, n = 6; I/R + veh, n = 6 hearts.
*p < 0.01 versus all groups; significance determined by one-way ANOVA.

activation, compared with PC hearts
(Figure 4C). Notably, GTS21 treatment
of I/R hearts attenuated this response to
that observed in nonischemic perfused
hearts (Figures 4C, D). Phosphorylation
of AKT (protein kinase B) (Figure 4C) as
well as ERK1/2, STAT3 and AMPK was
not affected by the treatment conditions
studied (data not shown).
`7nAChRs Are Expressed in Cultured
Cardiomyocytes
We used primary cultures of NRVMs
and an immortalized adult human ventricular myocyte line (AC16) to further
investigate the molecular mechanisms
by which α7nAChR activation may

provide cytoprotection in the ischemic
heart. Immunoblot analysis showed
that α7nAChR protein was expressed in
NRVM and AC16 lysates (Figure 5A).
To further confirm that α7nAChRs are
expressed on AC16 cells, which had
not been previously reported, freshly
dissociated cells were incubated with
primary antibody directed at the extracellular amino-terminus of α7nAChR,
then labeled with fluorescent-conjugated
secondary a ntibody and analyzed by
FACS (Figure 5B). The contour map
(left panel) shows the distribution of
cells, sorted by intensity of fluorescence
(x-axis) of the anti-α7nAChR antibody versus forward scatter (y-axis).
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These data are quantified in the histogram (right panel) as cell count to
antibody fluorescence intensity. The
α7nAChR antibody binding to AC16
cells is represented by the higher fluorescence intensity peak-b, and this binding
was largely prevented by preadsorption with the peptide immunogen, as
indicated by the shift of peak-b to the
lower-intensity peak-a. Peak-c represents
cells incubated with isotype control IgG.
These data confirm the presence of
α7nAChR on AC16 cell membranes.
Fluorescence microscopy was used
for immunolocalization of α7nAChRs in
NRVMs. In Figure 5C, cells that stained
for F-actin also showed strong fluorescence staining for α7nAChRs (a7nR),
whereas F-actin–positive cells incubated
with isotype control IgG showed no
cell-specific fluorescence. Exposure times
and wavelength settings were identical
for these cells, grown on two separate
coverslips. Micrographs in Figure 5D
show NRVMs plated on separate coverslips incubated with either anti-α7nAChR
antibody or the isotype control IgG,
showing strong α7nAChR (a7nR) immunofluorescence localized to myocytes
above the IgG background fluorescence.
Laser settings and exposure times were
identical in these two micrographs.
`7nAChR-Activated Signaling Events
in Cultured Cardiomyocytes
NRVMs were cultured to study the
time course of α7nAChR-initiated activation of intracellular signaling pathways under conditions of hypoxia/
reoxygenation and normoxia. Based on
preliminary studies using 1 × 10-9, 10-8
and 10-7 M GTS21, we determined that
10-9 M was optimum for activation of
signaling pathways in these cell-based
experiments. Quantitation of immunoblot analysis showed that after 8 h of
hypoxia, reoxygenation significantly increased phosphorylation of JNK within
10 min, and this effect was abrogated by
GTS21 treatment (p < 0.05) (Figure 6A).
In contrast to the results in perfused
hearts, phosphorylation of p38MAPK in
NRVM was not altered significantly by
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(p < 0.001); however, cells treated with
GTS21 (10-9 M and 10-8 M) had significantly higher intracellular ATP, similar
to levels measured under normoxic
conditions (Figure 7A). Pretreatment
with MLA completely blocked this effect
of GTS21 (Figure 7B). MLA treatment
alone had no effect on cellular ATP content (data not shown).

Figure 4. Intracellular signaling pathway activation in isolated perfused rat hearts exposed to I/R. (A) Representative Western blots (WB) showing α7nAChR protein content in
rat LV of in vivo and ex vivo models of I/R injury treated with GTS21 or vehicle; PC, perfusion control; no statistical differences among groups (n = 4–5/group). (B) Quantitation of
immunoblots in (A) showing α7nAChR normalized to GAPDH. (C) Representative immunoblots for JNK, p38MAPK, AKT and their phosphorylated isoforms in I/R perfused LVs treated
with vehicle or GTS21. (D) Quantitation of the WB shown as bar graphs for phospho-JNK
to total JNK and p-p38MAPK to total p38MAPK ratios normalized to PC. Values are mean ± SE;
*p < 0.01 versus all groups. Statistical significance determined by one-way ANOVA.

either reoxygenation or GTS21 treatment
(Figure 6B). Rapid phosphorylation of
Erk1/2 in response to GTS21 occurred
under normoxic conditions (Figure 6D),
and although this response was also observed during reoxygenation, it did not
reach statistical significance (p = 0.07)
(Figure 6C). Additional signaling
pathways that were interrogated but
showed no effect of GTS21 treatment
included Akt, AMP-activated kinase,
Jak2/Stat3 and DUSP4 (dual-specificity
phosphatase) (data not shown).

GTS21 Increases Intracellular ATP
Concentration after I/R
Since GTS21 treatment preserved
mitochondrial membrane potential and
improved contractility early in the reperfusion period, we measured intracellular
ATP concentration. AC16 cells were
exposed to 6 h hypoxia followed by 1 h
reoxygenation (H/R) with or without
GTS21 treatment and compared with
cells cultured in normoxic conditions.
As expected, ATP concentration in cells
exposed to H/R decreased by 35%

DISCUSSION
The key finding in this study is that
activating nicotinic acetylcholine receptors in the myocardium significantly reduced ischemia reperfusion injury, with
improvement in contractile function as a
result of a significant reduction in infarct
size and preservation of mitochondrial
membrane potential, maintenance of
intracellular ATP concentration, reduced
tissue ROS and inhibition of intracellular
stress pathway activation. Secondly,
these effects were independent of a systemic inflammatory response, since the
ex vivo perfused heart preparation that
was isolated from peripheral immune
and central nervous systems showed an
immediate improvement in contractility
at the onset of reperfusion in response
to treatment with a selective α7nAChR
agonist, GTS21. In addition, results from
in vivo I/R studies showing a significant
improvement in all measures of left ventricular function within 1 h of reperfusion following GTS21 treatment suggests
that the protective effects of nicotinic receptor activation may be independent of
peripheral immune responses to injury.
Although other studies have reported
that cholinergic receptor stimulation
reduced inflammation and/or leukocyte
infiltration into sites of ischemic injury
in organs including the heart and kidney
(3,43,49,51), it remains plausible that
the reduced trafficking of leukocytes to
sites of injury is secondary to the direct
actions of cholinergic receptor-mediated
increases in cell survival and function.
Yeboah et al. (51) showed that renal
damage after I/R was similarly reduced
in both vagotomized and control animals
following nicotine treatment. Calvillo
et al. (3) showed that vagus nerve
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Figure 5. Localization of α7nAChRs in cultured cardiomyocytes. (A) Immunoblot analysis
of α7nAChR (55 kDa) in total lysates of neonatal rat ventricular myocytes (NRVM) and
adult human cardiomyocytes AC16. (B) FACS analysis of intact AC16 cells sorted by
intensity of bound anti-α7nAChR antibody versus forward scatter (FSC). Contour map
(left) shows distinct populations of cells that are quantified in the histogram (right): cells in
peak-b are bound with fluorescence-labeled antibody; cells in peak-a were incubated
with antibody preadsorbed with peptide immunogen; cells incubated with isotype control IgG are in peak-c. (C) Fluorescence microscopy localized α7nAChR (a7nR) in NRVM
using a rabbit anti-α7nAChR antibody and FITC-labeled secondary antibody. Counterstaining with TRITC-labeled phalloidin identified F-actin in cardiomyocytes. Using identical
exposure settings, isotype rabbit IgG showed low background fluorescence in myocytes
stained for F-actin. Scale bars represent 20 μm. (D) Micrographs taken at the same exposure settings show strong localization of anti-α7nAChR antibodies to NRVMs while the IgG
isotype control is weakly fluorescent. Scale bars, 20 μm.

s timulation limited infarct size in an animal model of I/R and, by 24 h, reduced
macrophage/neutrophil infiltration at
the site of injury. Given that these effects
were partially blocked by a nonselective
nicotinic receptor antagonist, further
suggests that both pharmacologic and

neural activation of cholinergic receptors
could be cardioprotective.
Delfiner et al. (8) and others (1,41)
have identified postganglionic cholinergic nerve fibers in the ventricular
epicardium that stain with anti–choline
acetyltransferase antibody, indicating
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that these neurons are a local source
of acetylcholine. Recent studies have
also identified the cardiomyocyte as a
nonneuronal source of acetylcholine
synthesis and secretion. Acting in an
autocrine/paracrine manner, acetylcholine has been reported to limit myocardial tissue injury in ischemia and
reduce cardiac remodeling in response
to hypertrophic signals (15,36), thus
providing a rationale for therapeutic
targeting of cholinergic receptors in the
heart. We initially focused the present
study on the α7 subtype of nAChR
due to its central role in mediating the
antiinflammatory effects of cholinergic
stimulation (38,47) (reviewed in [34]).
The presence of α7nAChRs in myocytes
and coronary vessels of the heart (10)
and published reports localizing these
receptors to mitochondria suggest a role
beyond an inflammatory one (11,29).
Herein, we identified α7nAChRs in rat
heart homogenates, in cultured primary
neonatal rat ventricular myocytes and
in a human cardiomyocyte cell line. We
did not observe any changes in myocardial α7nAChR protein expression in
response to I/R or with GTS21 treatment
in either ex vivo or in vivo experiments.
Studies have suggested that α7nAChR
desensitization occurs in response to endogenous ACh that is known to increase
in the myocardial interstitium during
ischemia (20), so that an allosteric modulator of α7nAChR such as galantamine
may augment the effects of endogenous
ACh (44,48). Galantamine at higher
concentrations also functions to inhibit
acetylcholinesterase. These activities
may partially explain the positive effects
of galantamine on LV function in the
perfused I/R hearts, although no additive effects were seen when GTS21 was
combined with galantamine. The effects
of GTS21 on LV function and cell signaling were blocked by MLA, a selective
α7nAChR antagonist, providing further
evidence that these responses required
α7nAChR activation.
To understand how α7nAChR activation resulted in reduced infarct size
and decreased tissue ROS after I/R,
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Figure 6. α7nAChR-activated intracellular signaling pathways in cultured cardiomyocytes.
NRVM cultures exposed to 8-h hypoxia (HX) followed by reoxygenation (RO) with or
without GTS21 (10-9 M) treatment; n = 4/time point; Western blots show total and phosphorylated protein kinases. Bar graphs show the quantitation of immunoreactive bands
(AU, arbitrary units). (A) ANOVA was used to determine statistical significance among
p-JNK/JNK values at 10, 20, 40 min. RO versus HX at 0 min. *p < 0.01; two-tailed Student t
test was used to determine statistical significance between untreated and GTS-treated
cells at the same time point #p < 0.05 at 10, 20, 40 min. RO + GTS versus RO at 10, 20, 40
min, respectively. (B) p-p38MAPK to total p38MAPK and (C) pERK1/2 to total Erk1/2. (D)
NRVMs under normoxic (NMX) conditions treated with GTS21 showing pERK1/2 /ERK ratios;
#
p < 0.05 versus (-)GTS at 0 min.

we examined mitochondria that play a
critical role in cell death and ROS generation in ischemia (30). We found that the
mitochondrial membrane potential was
elevated in I/R hearts that would favor
ROS formation, and that GTS21 treatment
normalized mitochondrial membrane
potential. It is interesting to speculate
that this effect was mediated by
α7nAChRs expressed in mitochondria,

as reported Gergalova et al. (11), who
showed that α7-specific agonists decreased intramitochondrial Ca2+ accumulation and cytochrome c release
after H2O2 stimulation. Additionally,
these authors showed that α7nAChR
co-precipitated with the voltage-dependent anion channel, suggesting
a role in mitochondrial permeability
transition. To further address the role

of mitochondria, we used cultured cells
exposed to H/R to mimic cardiac I/R,
and, as expected, intracellular ATP concentration was decreased significantly.
However, GTS21 treatment during the
reoxygenation period normalized ATP
content, and this effect was abolished
by MLA p
 retreatment, supporting a
α7nAChR-mediated effect.
Several studies have shown that nicotinic receptor activation stimulates cell
survival pathways, including PI3K-Akt
and ERK1/2 protein kinases, and the
Jak/STAT signaling pathway in various
cell types, including macrophages and
kidney cells (6,46,52). We found that
I/R-induced activation of two stress
kinase pathways, p38MAPK and JNK,
were attenuated by GTS21 treatment,
and that phosphorylation of ERK1/2
was increased, similar to mechanisms
reported for ACh treatment of cultured
cardiomyocytes exposed to hypoxia.
These results suggest that agonists of
nicotinic receptors may enhance cell
survival under hypoxia reoxygenation
conditions, either directly or indirectly,
by activating intracellular survival
pathways. In contrast, other studies
using various types of cultured cardiomyocytes support a role of muscarinic
receptors in ACh-mediated protective
effects during hypoxia including activation of the PI3K/Akt/HIF1α signaling
pathways (15), or inhibition of TNFα
production and p38MAPK/JNK signaling (27). It is well established that activation of α7nAChRs on macrophages
inhibits production and release of
TNFα (34,47). Thus the distinct role of
nicotinic versus muscarinic receptors on
these mechanisms in the heart remains
to be determined and is of particular
importance should pharmaceuticals
targeting specific receptors subtypes
be developed to treat myocardial I/R
injury. Alternatively, activation of nicotinic receptors localized to coronary
vessel endothelial and smooth muscle
cells (10,46) may reduce vascular dysfunction after I/R, thus improving perfusion of the myocardium, resulting in
preserved contractile function.
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Figure 7. Effects of GTS21 on intracellular ATP. AC16 cells were exposed to 6-h hypoxia
followed by 1-h reoxygenation (H/R)(+) or cultured under normoxia (-) conditions. Cellular ATP content was measured using a luciferase assay and normalized to total protein.
(A) Cells were treated with GTS21 (1, 10 nM) only during reperfusion. (B) Pretreatment
with MLA (100 nM) abolished the GTS21 effect on H/R cells. Data (mean ± SE) represents
n = 3–6 cell culture dishes/treatment group. Each ATP assay data point was done in
triplicate. Significance was determined by ANOVA post hoc Newman-Keuls; *p < 0.01
differences between groups as indicated by the connecting line.

CONCLUSION
In conclusion, our data are consistent
with the idea that in a setting of cardiac ischemia reperfusion, activation
of α7nAChRs stimulates prosurvival
signaling pathways or inhibits stress
signals, leading to the preservation of
mitochondria, which reduces ROS generation and increases cellular ATP, all
of which attenuates tissue injury and
improves cardiac contractile function.
Furthermore, targeting nicotinic cholinergic receptor pathways by pharmacologic means or neuromodulation has the
added benefit of dampening subsequent
systemic inflammatory responses in
which cytokines released from damaged
tissue promote leukocyte trafficking to
the site of injury (3, 37,50).
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